Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNDUCT - GETUG V08
2024-516077-72-02Phase 2Authorised
- Sponsor
- CHU Nîmes
- Start
- Nov 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in upper tract urothelial carcinoma (UTUC) (2 arms), sponsored by CHU Nîmes. Primary endpoint: Pathological complete response rate. Planned start Nov 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2024-516077-72-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516077-72-02.